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ABSTRACT 
 
The aim of the thesis was twofold. The first aim was to radiolabel small molecules by 
using carbon-11 and fluorine-18 for visualising beta cell mass (BCM) in the pancreas by 
PET. Diabetes Mellitus (DM) is a chronic metabolic disorder that results from an absolute 
or relative lack of BCM of endocrine pancreas. The lack of an adequate non-invasive 
imaging PET probe prevents detailed examination of beta cell loss during onset and 
progression of DM as well as development of novel treatments and islets transplantation 
progress. The second aim of the thesis was to radiolabel peptide molecules with fluorine-18 
to visualise beta amyloid in Alzheimer’s disease (AD) brain. AD is a chronic, progressive 
neurodegenerative disorder. Brain penetration study of a labelled peptide, specific for beta 
amyloid that can cross blood-brain-barrier (BBB), is important to gain knowledge about the 
fate of the molecule as a diagnostic probe. 
A series of three novel radioligands for BCM imaging has been developed in this 
thesis. In paper I, a vesicular monoamine transporter type 2 (VMAT2) specific radioligand 
[18F]FE-DTBZ-d4 was synthesised in two steps. First step is the nucleophilic 
[18F]fluorination to produce deuterated-[18F]fluoroethylbromide followed by the O-
alkylation of desmethyl-DTBZ precursor to produce [18F]FE-DTBZ-d4. The in vivo 
pharmacokinetics (PK) studies in pigs by PET/CT demonstrated reduced in vivo 
defluorination; therefore, it may be an improved potential candidate for imaging VMAT2 
dense tissue i.e. islets transplantation in proximity to cortical bone structure. In Paper II, a 
glucokinase (GK) specific radioligand, [11C]AZ12504948, was synthesised in one step via 
alkylation of O-desmethyl precursor using [11C]methyl iodide. Both in vitro and in vivo (pig 
and monkey) studies with [11C]AZ12504948 for imaging GK in the pancreas and liver 
indicated low specificity. Increased target specificity is required for further progress in GK 
imaging using PET radioligands. In Paper III, a radioligand for G-protein coupled receptor 
44 (GPR44), [11C/3H]AZ Compound X, was synthesised via S-methylation of sodium 
sulfinate salt in one step using [11C/3H]methyl iodide. In vitro binding of the radioligand, 
evaluated by autoradiography (ARG) on human and rat pancreatic tissues, confirmed higher 
specific binding in islets of human pancreatic tissue and no measurable binding in rat 
pancreas, which is devoid of GPR44. These studies indicate that the radioligand has suitable 
properties for beta cell imaging with high potential for further preclinical and clinical 
evaluation. 
Three novel D-peptides were radiolabelled with fluorine-18 ([18F]ACI-87, [18F]ACI-
88, [18F]ACI-89) by using prosthetic group N-succinimidyl-4-[18F]fluorobenzoate, [18F]SFB, 
with epsilon (ε)-amino groups of lysine residues of peptide precursors in two steps. First step 
is the synthesis of [18F]SFB followed by the addition of [18F]SFB via acylation to the 
peptide molecule. Trimethylammonium salt [N(CH3)3+] precursor for synthesising [18F]SFB 
as well as the reference standard SFB were synthesised with good yields. Three 19F-peptide 
reference standards were also synthesised by using SFB. Preliminary ARG measurements 
were performed in AD and control human brains. ARG demonstrated higher radioligand 
uptake in the AD brain compared to age-matched control brain, which makes them 
potential for further use in in vivo testing by PET. However, preliminary PET (in vivo) 
studies in cynomolgus monkey brain, using these 18F-D-peptides, confirmed too low BBB 
penetration, making them unsuitable for further use as in vivo PET probes. 
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1 INTRODUCTION 
 
Henri Becquerel discovered natural radioactivity in 1896, immediately after the 
discovery of X-rays by W. C. Röntgen. The research on radioactivity was further investigated 
by Marie Curie and her husband Pierre Curie, and they were able to isolate natural 
radioactive elements in 1898. The discovery of this natural radioactivity had great scientific 
sensation at that time and still has tremendous implications in our lives. Suddenly, several 
new elements were discovered that emitted different types of radiation but were chemically 
identical with already known elements, and to solve the problem, the concept of isotopes 
(Greek; iso=same, tope=place) was introduced by Soddy in 1913. Almost at the same time 
(1913), the practical implication of the isotopic theory was demonstrated by George de 
Hevesy and his colleagues in the field of inorganic chemistry1. De Hevesy was also the first 
one to use the radioactive tracer technique in biology by using the radioisotope lead-212, 
212Pb, to investigate lead uptake in plants2 and radiotracer phosphorous-32, 32P, to study the 
tracer distribution in rats3. So far, for the radioactive nuclides used in these studies, nature 
was the supplier. 
  
1.1 MOLECULAR IMAGING USING PET 
 
New era of tracer technique using radiation started with the discovery of artificially 
induced radioactivity by the couple Irene Curie and Frédéric Joliot in 1934. They 
demonstrated the production of artificial radioactive isotope (30P) with short half-life (t1/2 
=3.15 min), by bombarding aluminium foil with alpha particles via the nuclear reaction 
27Al(α,n)30P4. They also suggested that it was possible to produce similar radioactive 
elements with different nuclear reactions by using different bombarding particles, such as 
protons, neutrons and deuterons4. This hypothesis was proved to be true by Ernest Lawrence 
et al. in Berkeley, California who had already started working with accelerating particles 
between two D-shaped magnets, called a cyclotron, to produce high energy protons and 
deuterons that could bombard elements to explore the nature of the atomic nucleus5. In the 
same year (1934), with the progression of increased size of the cyclotron, Lawrence and 
Livingston et al. could produce large quantities of artificial short lived radioisotopes, 
including carbon-11, nitrogen-13, oxygen-15 and fluorine-186, which have subsequently been 
proved to have great significance in biomedical science, research and clinical practice today.  
The term molecular imaging can be defined as the non-invasive visualisation of 
biological processes in vivo at the molecular or cellular levels using specific imaging 
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tracers7,8. Positron emission tomography (PET) is a non-invasive molecular imaging (in vivo) 
technique that allows for the localisation of a molecule labelled with positron emitting 
nuclides9, based on the detection of positron annihilation radiation and subsequently 
processing of raw data onto an image10, 11. PET was developed at the end of 1970s12-14, but 
the full potential of the technique was not acknowledged outside the scientific community 
until 1990s15. Numerous studies with 18F-labelled deoxyglucose ([18F]FDG), developed by 
Ido et al.16, using PET scanners demonstrated how accumulation of [18F]FDG in cancerous 
lesions helped by giving a solution for many problems by means of diagnosis and prognosis 
with cancer patients17-20. Nowadays, PET is frequently used for early detection, 
characterisation, real time monitoring of diseases as well as investigating the effectiveness of 
therapeutic drugs7. PET can provide the molecular interactions between the tracer molecule 
and the biological target, e.g. a protein, transporter, enzyme function and inhibition, 
metabolism and general biochemical function. PET has become a powerful functional 
imaging tool, and the most used application of PET imaging is implemented in oncology21, 
neuroscience22, 23 and cardiovascular diseases24, 25.  
Another major utility of PET imaging is to understand and facilitate drug action and 
development26-28, which can be investigated in two ways. First, actual drugs or new drug 
candidates can be radiolabelled, and pharmacokinetics of the drug such as absorption, 
distribution, metabolism and excretion (ADME) can be studied by PET29, 30 using the 
microdose concept i.e. maximum doses of ≤100 µg or 1/100th of the therapeutic doses are 
used31. Based on early in vivo PET studies, costly failures32 of ‘go’ or ‘no go’ decisions can 
be made in very early stages of drug development. The second area is to evaluate 
pharmacodynamics or dose finding studies through receptor occupancy30, 33, 34. Several well 
characterised PET radioligands have been used to measure receptor occupancies of 
antipsychotic drugs35-37 and the relationship between receptor occupancy, clinical usefulness 
and side-effects38-40. 
 
1.2 HOW DOES PET WORK 
 
PET imaging agents are radiolabelled with positron emitting radionuclides, such as 11C, 
18F, 13N and 15O, which are the radioisotopes of the stable natural elements of 12C, 19F, 14N 
and 16O, respectively, and they decay (with different half-lives, Table 1) by the emission of a 
positively charged particle, called positron. For example, 11C-radioisotope decays by positron 
emission and forms the stable nuclide boron, 11B. When the labelled compound (radiotracer 
or radioligand) is administered intravenously in vivo, the emitting positron from the radio-
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nuclide travels a short distance in the surrounding matter or wet tissue where it collides with 
its antiparticle, an electron, and consequently annihilates. This annihilation results in emission 
of two 511 KeV gamma rays (photons), which travel approximately 180˚ apart from each 
other and are detected by an array of surrounding gamma ray detectors of the PET scanning 
device (Figure 1). Photons, which are registered only in pairs (within few nanoseconds) by 
the PET scanner, are considered to be originated from the same source and thereby, the 
position of the positron. The distribution of the radioactivity is then visualised and quantified 
as a function of time41 after reconstruction11 and appropriate correction for scatter and 
random coincidences. The distance travelled by the positron in the surrounding tissue before 
annihilation is known as positron range. The emitted positron energy is different for each 
radionuclide, which determines the travel length of the positron before annihilation (Table 1). 
The larger the positron energy, the longer the average distance the positron travels before 
annihilation and the larger the loss in spatial resolution42. 
 
 
Figure 1. Schematic diagram representing acquisition and reconstruction of PET images.43  
Table 1. Physical properties of commonly used positron emitting radionuclides 
              (the shorter the half-life, the higher the SRA value). 
 
Radionuclide Half-life (T1/2=min) 
Maximum 
Energy 
(MeV) 
Max linear 
range in water 
(mm) 
Theoretical 
SRA 
(GBq/µmol) 
15O 2.04 1.72 8.20 3.4×106 
13N 9.96 1.19 5.39 7.0×105 
11C 20.4 0.96 4.12 3.4×105 
68Ga 67.6 1.899 9 1×105 
18F 109.7 0.635 2.39 6.3×104 
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1.3 DEVELOPMENT OF PET RADIOLIGANDS 
 
The real challenge in PET molecular imaging is the search for the ‘optimal’ ligand. 
This development requires a multidisciplinary approach regarding; molecular target and 
radionuclide selection, organic synthesis, production of radionuclide, radiolabelling, quality 
control, in vitro and in vivo evaluation, detection of radiation, tomographic reconstruction, 
and finally, the application of a series of corrections to provide image representative of the 
ligand distribution in the live animals or human. In order to be able to develop a successful 
innovative radioligand, some important parameters need to be taken under consideration27, 44 
which are discussed below. 
 
1.3.1 Time aspects  
 
In syntheses using short-lived radionuclides, time is more important than in 
conventional synthetic work45-47. The 11C decay curve and the yield curves (Figure 2) indicate 
the importance of optimising synthesis time in relation to the labelled product formation. The 
length of the radiosynthesis and purification time should be as short as possible, and the 
radionuclide incorporation in the synthetic route should be as late as possible due to short 
half-lives of the radionuclides. To minimise the losses of radioactivity due to radioactive 
decay, work up procedure should be optimised to maximise radiochemical yield (RCY) and 
specific radioactivity (SRA)47, for example, solid phase extraction (SPE) purification is more 
desirable than high performance liquid chromatography (HPLC), microwave heating more 
than conventional heating47, 48 to speed up the process. In radiochemistry, it is also important 
to remember that the labelled precursors (11C or 18F) are produced in very low amounts; 
therefore, by increasing the amount of non-labelled reactants/precursor (103-104 fold of 
labelled precursor), one can increase the reaction rate and rapid formation of the radiolabelled 
product.  
 
 
 
Figure 2. Decay curve for 11C (dotted line), 
chemical yield in a hypothetical chemical 
reaction involving only stable nuclides 12C 
(solid line), and decay-corrected RCY using 
same reaction but including11C-(bold-line)7. 
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1.3.2 Binding affinity 
 
Binding affinity means how tightly a ligand binds to its target e.g. receptor, 
transporter or enzyme. Affinity is denoted as Kd and it can be expressed as the inverse 
equilibrium dissociation constant i.e. Kd=koff/kon. The required affinity mainly depends on the 
concentration of binding sites (Bmax) in the region of interest. A low concentration of binding 
sites means the affinity of the radioligand must be high (low Kd). Since sites are easier to 
saturate, the SRA of the ligand needs to be sufficiently high. It is preferable if Bmax is higher 
than Kd by one order of magnitude, i.e. if Bmax exists at nanomolar concentration, Kd should 
have subnanomolar concentration for good image contrast44. Typically, the most successful 
ligand have subnanomolar or low nanomolar affinity to the target of interest in vitro. A 
binding potential (BP), ratio of Bmax/Kd, value > 5-10 can be used as a rule of thumb49, 50 the 
higher the ratio, the more sensitive the signal.  
 
1.3.3 Specificity, selectivity and sensitivity 
 
The characteristic of a binding site or receptor to be activated only by a single 
molecule or class of molecules is known as specificity. The selectivity can be defined as 
relative affinity of the radioligand to the region of interest over other binding sites. If the 
biological target is well separated from the nonbinding site, then ligands with low selectivity 
can also be considered.  High specificity and selectivity is required for low dense receptor site 
to get good signal to noise ratio. Many radioligands fail in early stages due to high non-target 
binding i.e. binding to a target or tissue other than the site of interest51. The sensitivity is 
affected by other factors such as kinetics, surrounding-tissue uptake, spatial resolution, data 
handling, etc. 
 
1.3.4 Lipophilicity 
 
During the development of a new radioligand, lipophilicity (log P) of a molecule 
plays an important role, since non-specific interaction in addition to the tissue or target 
increases with increased lipophilicity49 i.e. specific-to-nonspecific binding ratios. For 
example, high lipophilic molecules tend to bind to plasma protein, thus, resulting in a 
reduction of free fraction in the blood and reduced delivery of the ligand to the specific sites. 
In contrast, molecules with low lipophilicity have higher water solubility, thus, faster 
clearance through the kidneys and limited blood-brain-barrier (BBB) penetration. Therefore, 
to find an optimal log P value is a challenge during radioligand development. The 
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recommended log P value to cross the BBB is between 1 and 3.5, preferably less than 352. 
Lipophilicity can influence a drug’s or ligand’s pharmacokinetics i.e. ADME53. For example, 
high lipophilic compound is eliminated mostly via the liver, thus, confounding PET images 
of nearby tissues, e.g. in this thesis, the pancreas. Due to high uptake or nonspecific binding 
near gastrointestinal tract, delineation of pancreas is troublesome, consequently affecting the 
specific uptake. However, lipophilicity and thereby elimination path can be altered by 
designing the ligand to be more hydrophilic upon addition of various amide linkers54 or by 
incorporation of a fluorine atom; replacement of a hydrogen atom by fluorine in an aliphatic 
position generally decreases the lipophilicity, while substitution in an aryl group increases the 
lipophilicity55. Lipophilicity can be calculated theoretically in advance by using computer 
programs56 or practically by the logarithm of the partition coefficient ratio between octanol 
and water/buffer at physiological pH.  
 
1.3.5 Specific radioactivity (SRA) 
 
SRA is defined as the concentration of a radioactive material in a sample, and is 
expressed as the radioactivity of the labelled compound divided by the molar amount of the 
compound (Bq/mol). In this thesis, SRA is expressed as GBq/µmol. The higher the SRA, the 
less the amount of ligand used, consequently, minimising the risk of saturation of the binding 
sites, as well as less risk of perturbation of the investigated biological system with unlabelled 
counterpart. For low density receptor binding sites, the SRA of the radioligand is very 
important and can limit its usefulness as an imaging agent. Even a small amount of injected 
cold ligand may lead to significant receptor occupancy and decrease the signal-to-noise ratio 
while possibly inducing pharmacological effects. For receptor-ligand interaction studies, high 
SRA is required to quantify the number of free receptors followed by drug occupancy. In 
contrast, for drug distribution studies or labelled endogenous compounds, SRA is not that 
important. Theoretical SRA values of PET radionuclides are very high, since they have short 
half-lives (Table 1). Due to isotopic dilution with its stable element, it is impossible to reach 
the theoretical SRA values with 11C and 18F radioligands. Despite isotopic dilution, the 
obtained SRA of 11C and 18F radioligand is sufficiently high enough to follow biochemical 
and physiological processes. For example, in clinical settings with consistent production of 
the radioligand, [11C]AZ Compound X, with SRA>1000 GBq/µmol on average and in 
combination with weight of human (60-80 kg), the estimated administered chemical amount 
of the carrier following injection of 300 MBq would be <0.001 µg/kg [Paper III]. 
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1.3.6 Radiolabelling and radiometabolism 
 
The position of the radiolabelling is not critical for in vitro studies (e.g. frozen tissue 
autoradiography), since radioligand metabolism is not expected. In contrast, ligand 
metabolism occurs throughout in vivo PET studies; therefore, the position of the labelling is 
very important. The PET scanner is unable to distinguish between radiochemical entities, 
since it can measure only radioactivity. As a result, if a radiometabolite enters the target, it 
will confound PET images with background radioactivity, which is not associated with the 
biological process under study; especially if the radiometabolite has some degree of target 
selectivity57. Therefore, a labelling position should be chosen carefully so that it is 
metabolically stable, preferably during the PET investigation, or, alternatively, labelled 
metabolites are hydrophilic enough and consequently eliminated quickly. For example, 
metabolic loss of 18F in vivo can be reduced by replacing hydrogen atoms with deuterium58 
(Paper I of this thesis) and can change the rate of reaction59. The rate of metabolism of a 
radioligand and the lipophilicity of radiometabolites can be estimated quantitatively using 
radio-HPLC technique60; moreover, radiometabolites can be identified with the help of highly 
sensitive LC-MS/MS61, 62 techniques. 
 
1.4 STRATEGIES FOR CARBON-11 LABELLING  
 
As a key element of life, carbon is of special interest for labelling compounds, 
including endogenous as well as other naturally occurring bio-molecules. Replacement of 
naturally occurring 12C by 11C does not alter the (bio)chemical properties of a molecule. The 
choice of radionuclide is 11C for radiolabelling during investigation of drugs for drug 
development or to measure biochemical processes. Since 11C has short half-life, longitudinal 
in vivo studies can be performed on the same day on the same subject. Many synthetic routes 
to 11C-compounds are already available (Figure 3) and several others are currently under 
development. Primary 11C-precursors are mainly [11C]CO2 and [11C]CH4, which can be 
produced by the same nuclear reaction in nitrogen gas targets containing trace amounts of 
oxygen and hydrogen gas, respectively (Figure 3). Target produced [11C]CO2 gives lower 
SRA due to unavoidable isotopic dilution; nonetheless, different secondary 11C-precursors 
can be prepared from [11C]CO2 by online or in one-pot procedures, which can give high SRA 
such as [11C]cyanide ([11C]CN)63 and [11C]carbon monoxide ([11C]CO)64, 65. Secondary 11C-
precursors [11C]CH3I, obtained via gas-phase method66 from target produced [11C]CH4, can 
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The most widely used methylating agent [11C]CH3I, introduced in 1970s68, 69 was 
mainly used for methylation on nitrogen, oxygen and sulfur containing nucleophiles with the 
corresponding desmethyl precursors44, 47. [11C]CH3I can be produced either by the “wet” 
method or by the “dry” method70. Besides [11C]CH3I, carbon disulfide, [11C]CS2 was 
introduced as 11C-labelling reagent for an effective route to synthesise 11C-labelled 
organosulfur compounds71, and [11C]methyl triflate, [11C]CH3OTf72-74, has been utilised to 
improve the RCY in 11C-methylations. Recent development of the micro-reactor technology 
for radiosynthesis has some advantages over conventional laboratory methods such as purer 
products, higher yields and shorter reaction times due to superior heating and controlled 
mixing of reagent streams75, 76. The formation of carbon-carbon bond (11C-C) via nucleophilic 
addition of Grignard reagent to [11C]CO277 or via [11C]CN78, 79 were very popular; however, 
recently organometallic-mediated 11C-C cross-coupling reactions using Stille, Suzuki or 
Sonogashira have also emerged80-83.  
 
 
 
Figure 3. Routes of producing 11C-labelled radiopharmaceuticals.  
 
 
1.5 STRATEGIES FOR FLUORINE-18 LABELLING  
 
Fluorine atom (F) is generally not a constituent of biomolecules; nevertheless, 
substitution of hydrogen atom (H) or hydroxyl group (OH) from a molecule with fluorine 
atom is one of the most commonly used bioisosteric replacements to introduce F in 
radiochemistry as well as in drug development. The F and H atoms are quite similar in size; 
therefore, replacement with F for a H would induce minimum steric perturbations84. The 
capability of F atom to form hydrogen bonds due to its high electronegetivity makes it similar 
to a OH substituent, and due to nature of high-energy bonding with carbon, fluoro-organic 
pharmaceutical derivatives have improved pharmacological properties85. Therefore, almost 
20% of the marketed drugs today contain at least one fluorine substituent86. Incorporation of 
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fluorine into drug candidates can increase or decrease the lipophilicity without changing the 
size of the molecule or changing the rates of in vivo absorption, but still allows for the 
molecule to fit into its binding site87. According to radiochemistry point of view, fluorine-18 
is a very attractive choice for radionuclide, mainly for two reasons. First, longer half-life 
(T1/2), which allows radiochemist to perform multi-step synthesis as well as permitting 
transport of 18F-radioligands over considerable distances. It allows PET scans to be acquired 
over a few hours and consequently following biological processes with quite slow kinetics. 
Secondly, the mode of decay; fluorine-18 emits quite a low energy positron (maximally 0.635 
MeV), which on average has a short path in vivo (~2 mm in water) before its annihilation.  
The positron path is similar to the highest spatial resolution achievable with modern PET 
cameras today (2–4 mm for a clinical PET camera88 and 1–2 mm for a µPET camera89), 
therefore. optimal PET image quality compared to other PET radionuclides (Table 1).  
Fluorine-18 can be manufactured from the cyclotron in two chemical forms; 
[18F]fluorine gas (act as an electrophile) or [18F]fluoride (electron-rich and act as a 
nucleophile), which determines the possible reactions. The principal 18F-labelling methods 
are restricted to a few and can be divided into these two ways: electrophilic and nucleophilic 
substitution. 
1.5.1 Electrophilic substitution 
 
For electrophilic 18F-labelling reactions, carrier-added (c.a.) [18F]fluorine ([18F]F2) gas 
is used as electrophile and can be produced directly from the target. Two different types of 
nuclear reactions are available for producing elemental [18F]F2; 20Ne(d,α)18F90-92 and 
18O2(p,n)18F93, 94. In both cases, produced 18F is adsorbed on the target walls so that an 
addition of elemental F2 to the target gas is mandatory to extract the radioactivity; therefore, 
low SRA is obtained. The most common and practical process for producing [18F]F2 is 
20Ne(d,α)18F reaction even though higher RCY and SRA of [18F]F2 is achieved from 18O2 
target using 18O2(p,n)18F reaction (since two consecutive irradiations are necessary)94, 95. 
Electrophilic c.a. radiofluorination is limited to applications where low SRA is accepted such 
as endogenous compounds. Reported highest SRA in literature, obtained for [18F]F2, is 2 
GBq/µmol96, which has been improved to ~55 GBq/µmol (for ~7.5 GBq of [18F]F2) from 
[18F]F- produced from a water target97. However, high SRA is not only preferable but also 
mandatory for investigations of low concentration binding sites, e.g. BCM in pancreas, which 
is why only no carrier added (n.c.a.) [18F]fluoride form has been considered in this thesis. 
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1.5.2 Nucleophilic substitution 
 
Most of the 18F-labelled radiopharmaceuticals available and clinically used today are 
obtained from nucleophilic substitution reactions based on n.c.a. [18F]fluoride ([18F]F-), which 
is directly available from the target. The main reason behind the popularity of using 
[18F]fluoride is based on getting highest SRA, e.g. 5.2×103 GBq/µmol98. The nucleophilic 18F 
is achieved as fluoride ion in aqueous solution from 18O(p,n)18F nuclear reaction and 
delivered from the target to the hot cell. Due to high charge density of the anion, it is highly 
hydrated and inactivated for nucleophilic reactions. Therefore, strict exclusion of water is 
needed using [18F]F- as a nucleophile. This kind of reaction is also sensitive to the presence of 
trace amounts of metal ions co-eluting with [18F]F- from the target99. In the presence of Lewis 
acids, the [18F]F- has a strong tendency to form complexes and hence will be masked by ions 
of heavy metals. Moreover, [18F]F- is very easily protonated, forming hydrogen fluoride and 
hence becoming unavailable for the next reaction. Therefore, radiolabelling has to take place 
under aprotic but polar conditions. The [18F]F- is isolated and separated from the 18O-water as 
well as metal ions by passing through an anion exchange resin100. The retained [18F]F- is then 
eluted with an acetonitrile solution of kryptofix2.2.2 and potassium carbonate (K2CO3); 
subsequently, water is removed by azeotropic distillation with acetonitrile to produce ‘naked’ 
[18F]F- of high nucleophilicity. The Kryptofix2.2.2 (aminopolyether), in combination with 
K2CO3 or oxalate101, is mainly used as phase transfer catalysts (PTC) for further activation of 
the [18F]F- anion. Tetraalkylammonium hydrogencarbonates102, 103 can also be used as PTC 
and in some cases, it showed advantages over kryptofix for [18F]F- activation104, 105, especially 
if the precursor is sensitive to basic conditions. In general, nucleophilic substitution with 
[18F]F- occurs by heating (>100°C) the dried residue of [18F]F-/ K2CO3/kryptofix2.2.2 with right 
precursor, in presence of a polar aprotic solvent such as ACN, DMF, DMSO or o-DCB104.  
Nucleophilic substitution reaction with [18F]F- can be divided further into two 
categories: i) Direct fluorination (one step) via aliphatic and aromatic substitution and ii) 
Indirect fluorination (two steps) via 18F-labelled prosthetic group or synthon formation 
followed by a second reaction, such as alkylation, acylation, etc. The aliphatic nucleophilic 
substitution reaction proceeds via SN2-mechanism, where substitution takes place by [18F]F- 
ion on a precursor containing appropriate leaving group such as halogens (I, Br and Cl) or 
sulphonic acid ester groups, e.g.  mesylate, tosylate, nosylate, triflate, etc. The nucleophilic 
aromatic substitution (SNAr) is of even greater importance for 18F-labelled 
radiopharmaceuticals due to their greater metabolic stability. This reaction takes place with 
the presence of activating electron withdrawing group (EWG) in the ortho or para positions 
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relative to the leaving group106, 107. In particular, substituents with strong electron 
withdrawing properties such as nitro, cyano, carbonyl and trifluoromethyl groups are suitable 
for the activation step108, 109. Halogens (F, Cl, Br), nitro (NO2) and the trimethylammonium 
salts [N(CH3)3+] show increasing reactivity as the leaving group. The leaving group 
[N(CH3)3+] can be advantageous compared to NO2 due to better separation of the excess 
precursor from the final product; however, this precursor can lead to some competitive side 
reactions that can reduce RCY110-112. On the other hand, CN group as EWG might not be 
suitable, since CN is very sensitive to basic conditions, which can lead to undesired 
hydrolysis product than the desired radiolabelled product113.  
To avoid the presence of extra activating groups in the precursor molecule, many 
different approaches have been introduced in the radiochemistry field, such as heteroarenes 
(pyridine) labelling with 18F in the ortho positioned leaving group114-116. Introduction and 
extensive work on labelling of [18F]fluoroarenes using diaryliodonium salts117, 118 as well 
iodonium ylides precursor113, 119 have opened new door for radiochemists to explore a class of 
compounds that are not possible to synthesise via SNAr reaction120. 
1.5.3 18F-Fluorination via prosthetic groups (Papers I and IV) 
 
As mentioned above, indirect method is used in 18F-fluorination via prosthetic group. It 
means a primary 18F-compound is labelled by direct fluorination as described above (either 
by aliphatic or aromatic substitution), followed by coupling of 18F-compound i.e. prosthetic 
group, with a second molecule. Important procedures via prosthetic groups include: 
[18F]fluoroalkylation121, [18F]fluoroacylation122, 123 and [18F]fluoroamidation124. Application 
of prosthetic groups is most common for molecules carrying a protic functional group such as 
thiol, amino or hydroxyl group.  
18F-Fluoroalkyl agents such as [18F]fluoropropyl, ethyl or methyl are synthesised by 
substitution of halogens or sulfonate esters with n.c.a. [18F]F- 125, 126. 18F-Fluoroalkyl agents 
can be purified very easily via disposable Sep-Pak cartridges or distillation from the reaction 
mixture127, as they have low boiling point. This purification process of 18F-fluoroalkyl agents 
produces more chemically and radiochemically pure product as well as eliminates nonvolatile 
impurities, thus, increasing the RCY of the second reaction125, 126, 128, 129. Well-known 
aliphatic substitution reactions using 18F-fluoroalkyl agents include [18F]fluorocholine130, 
[18F]FET131 and [18F]β-CFT-FP132. In this thesis, in paper I, [18F]fluoroethyl was used as 
prosthetic group to radiolabel the hydroxyl group so that we could use same precursor for 
both 11C and 18F radiolabelling. 
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Many methods are available to label proteins and peptides; however, most common 
methods applied for labelling peptide with 18F is the prosthetic group approach133. The 
advantage of using the prosthetic group approach is that the peptide coupling reaction can be 
performed under mild conditions, thereby, preserving the integrity of the peptide, especially 
those that are heat and pH sensitive. The disadvantage is the multiple-step time-consuming 
synthetic procedure, which is an obstacle for widespread clinical applications. The most 
commonly used prosthetic groups are N-succinimidyl-4-[18F]fluorobenzoate, [18F]SFB and 
[18F]fluorobenzaldehyde [18F]FBA. In this thesis, in Paper IV, we have radiolabelled peptides 
with lysine group; therefore, [18F]SFB has been used for radiolabelling. [18F]SFB is an 
analogue of Bolton-Hunter reagent developed in 1973 for radioiodination of proteins134, and 
later on it has been successfully developed for PET radiolabelling135-137. The aromatic 
fluorine-carbon bond of [18F]SFB is more stable and less sensitive towards hydrolysis. 
Activated esters of N-hydroxysuccinimide are good electrophiles for conjugation to 
nucleophiles (amines of peptides), in order to form stable amide bonds. Based on all these 
observations, [18F]SFB was selected even though multiple radiochemical steps were required 
for its production. If aliphatic defluorination is not a concern, an alternative N-succinimidyl-
4-[18F]fluoromethyl benzoate, analogue to [18F]SFB can be produced in one step from a tosyl 
or nosyl leaving group138-140. The recent discovery and development of [18F]fluoride-
aluminum complex (Al18F) to radiolabel peptides also provided a good alternative for 
simplifying the labelling procedure141. Unfortunately, the current procedure for forming 
Al18F-NOTA complex also requires relatively high temperatures, which has reduced the 
scope of this method.  
 
1.6 RADIOCHEMICAL PURITY, PURIFICATION AND FORMULATION  
 
Radiochemical purity is defined as the fraction of the radioactive species that is in the 
desired chemical form. All PET radioligands, whether for human or animal use, need to 
possess a high level of chemical and radiochemical purity (typically >95%). To isolate 
radiolabelled probe in highest purity form, reaction mixtures (RM) need to be purified after 
radiolabelling, from other radioactive by-products as well as from precursor and other 
reagents used during synthesis. HPLC is the best choice to purify radioligand, while SPE 
cartridge can be used if other impurities are well separated from the radioligand. Generally, 
RM contains large amounts of organic solvents (e.g. acetonitrile, DMF, DMSO) and need to 
be diluted with water or buffer prior to injection on HPLC to avoid excessive peak 
broadening. The preparative HPLC column should be large enough to efficiently separate the 
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relatively large mass amount of precursor (typically 0.1–10 mg) from the trace amounts of the 
PET probe. For 18F-labelling, pre-purification of RM on an in-line SPE column is useful for 
the elimination of relatively large amounts of un-reacted radioactivity [18F]fluoride142. Any 
organic solvents used in mobile phase during preparative HPLC purification procedure that 
are not compatible with I.V. injection should be removed either by evaporation or by SPE, 
followed by desorption with ethanol. This step can be omitted if ethanol is used as an organic 
modifier in the mobile phase; however, due to high viscosity of ethanol it results in a higher 
back pressure in comparison with other organic solvents such as acetonitrile or methanol. 
The pure radioligand after HPLC purification is formulated by dilution with buffer or 
salt solution to achieve an isotonic injectable solution143, which is sterilised by sterile 
membrane filtration or by autoclave. To prevent radiolysis, scavengers such as ascorbic acid 
or sodium ascorbate or ethanol can be added144, and solubilising agents such as Tween-80 can 
be added to lipophilic radioligand formulations to reduce loss of radioactivity by means of 
adsorption during sterile filtration as well as in syringes and catheters during injection. 
 
1.7 COMBINE MODALITY (PET/CT) 
 
With the development of a prototype integrated PET/CT scanner, a revolution in 
medical imaging field occurred in 2000145. Lack of a clear anatomical reference frame and 
relatively low spatial resolution are some of the limitations of PET imaging alone. It is also 
even more difficult to accurately outline anatomic structure of small organs, such as pancreas, 
which is situated close to abdominal region, without help of structural imaging methods such 
as CT. Due to spill over of radioligand uptake from the kidney, liver or gastrointestinal tract 
(that exhibit higher nonspecific radioligand accumulation) and partial volume effect (PVE), it 
is nearly impossible to delineate the pancreas on the PET image. This limitation can be 
overcome by integrating functional and anatomical tissue information obtained by combined 
PET/CT module, which has increased both accuracy of the interpretation and confidence 
level of the image analyser. All the in vivo studies performed in this thesis were investigated 
using a hybrid PET/CT scanner. 
 
1.8 DIABETES MELLITUS 
 
The pancreas consists of mainly two tissue types: endocrine and exocrine. Only a small 
percentage (1–2%) of pancreatic mass (~100 g healthy human pancreas) is accounted for as 
endocrine tissue, which is scattered heterogeneously in Islets of Langerhans all over the 
exocrine pancreas. Islets are comprised of four different cell types: alpha, beta, delta and 
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pancreatic polypeptide (PP)-cells, and among them only beta cells secrete insulin in response 
to elevated blood glucose levels. In islets, beta cells are the most abundant cells (50–80%), 
followed by alpha cells (20–30%) and the rest are delta and pp-cells (Figure 4)146. The islets 
are well perfused and small in size (40–300 µm in diameter)147, and the number of beta cells 
may vary between healthy subjects148. Since beta cells are responsible for maintaining normal 
glucose levels in the blood, an adequate number of functional pancreatic beta cells are 
required. The collective beta cell numbers are referred to as beta cell mass (BCM), and the 
proper release of insulin in response to glucose is referred to as beta cell function (BCF). The 
loss of beta cells reduces insulin production and consequently causes diabetes. Diabetes 
mellitus (DM) is a metabolic disorder, characterised by hyperglycemia; moreover, it is one of 
the major causes of death and disability worldwide. In 2012, 1.5 million people died from 
diabetes149, and currently >340 million people are affected which will increase to around 522 
million by 2030150. Two different forms of diabetes are distinguished based on different 
pathogenesis: Type 1 (T1DM) or insulin dependent and Type 2 (T2DM) or insulin resistant. 
BCM is reduced significantly in both type 1 and 2 diabetes patients, compared to non-diabetic 
individuals. In T1DM, an autoimmune attack against pancreatic beta cells results in a rapid 
loss of endocrine BCM, close to >90%151 and in T2DM, insulin resistance and beta cell 
dysfunction build up a progressive reduction of BCM, ranging from 25% to 65%148, 152. 
People with either type of diabetes are at high risk of developing a range of complications, 
such as retinopathy, nephropathy, neuropathy and cardiovascular disease153, which can 
endanger their health and survival; consequently, the high costs of care increase the risk of 
catastrophic medical expenses154. 
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Figure 4. Schematic representation of the location of the human pancreas, Islets of Langerhans and its 
composition146, 155. 
 
1.8.1 Beta cell imaging (BCI) 
 
As discussed earlier, functional loss of BCM is associated with both T1DM and 
T2DM156. At present, most information on human BCM during the progress of DM is 
obtained from post mortem pancreatic biopsy studies, “as a golden standard.” In vivo biopsies 
of the pancreas for determination of BCM in either healthy or diabetic patients are associated 
with complications and therefore unacceptable in clinical studies157. The other functional 
clinical tests such as insulin/C-peptide concentration in the blood as a response to a stimuli, 
does not reflect on BCM, but rather BCF. Production of insulin in individual beta cells can 
increase significantly to compensate for the decreased total BCM. Consequently, we lack 
reliable, reproducible data on the actual progress in BCM during progress of T1DM and 
T2DM even at group levels. Importantly, we currently lack the tools to follow the fate of 
BCM longitudinally over time in individual subjects158.  
In T1DM, BCM and its function proportionally decline quite rapidly with the onset of 
hyperglycemia159, and in T2DM, diagnosis is sometimes not possible until several years after 
its onset160. Therefore, there is a real need for an accurate and noninvasive in vivo imaging 
technique to study the dynamic changes of BCM at onset and progression of the disease to be 
able to diagnose early stages of diabetes or at high risk of its development, as well as to 
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monitor the efficacy of new drugs or stem cell therapy or islet transplantation. An attractive 
approach to determine BCM in vivo is PET, which can detect very low concentrations in 
subpicomolar range27 of the radioligand in the target tissue, with high sensitivity. However, 
several challenges have to be met before developing a PET radioligand for detecting BCM, 
which is discussed later. The ideal radioligand and the target for BCI have not been found 
yet. Several 11C and 18F labelled PET radioligands, aiming at three different molecular 
targets, such as [11C]DTBZ161 and [18F]fluoropropyl (FP)-DTBZ (targets VMAT2)162, 163, 
[68Ga]exendin-4 (targets GLP-1R)164 and [11C]5-HTP (targets serotonin biosynthesis)165 have 
undergone initial clinical validation, but none of them could fulfil all criteria for a ‘perfect’ 
BCI agent. An important argument against the use of PET radioligands in endogenous BCM 
imaging is striking the scientific area, where several theoretical166, technical and biological 
limitations are discussed to determine if the sensitivity and specificity are good enough to 
detect subtle changes of BCM over time167, 168. However, PET imaging could be very fruitful 
to monitor efficacy of glucose lowering drugs for treating T2DM, islets transplantation 
efficiency and graft survival for treating T1DM patients and thereby, optimise islet 
transplantation procedures and detect postoperative complications. 
In this thesis, three different molecular targets have been explored by using three novel 
18F and 11C-labelled radioligands, [18F]FE-DTBZ-d4 (targets VMAT2, Paper I), 
[11C]AZ12504948 (targets glucokinase, Paper II)  and [11C]AZ compound X (targets GPR44, 
Paper III), for visualising native BCM in the pancreas by PET. 
  
1.9 ALZHEIMER’S DISEASE (AD)  
 
Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder and is one 
of the most common causes of dementia169, which gradually worsens with the lapse of time in 
middle or late life. Death occurs, on average, nine years after diagnosis170; nevertheless, the 
onset of the pathological processes occurs probably years prior to the onset of cognitive 
symptoms132. The amyloid hypothesis states that aggregated amyloid-beta (Aβ) peptides have 
a major role in the development of AD171, 172; therefore, in vivo imaging of Aβ plaques may 
be beneficial for the diagnosis, staging and treatment of AD. Over the last decade, the 
development of amyloid-specific PET radioligands has proved successful for distinguishing 
between AD and healthy controls. Most radioligands used for Aβ plaque imaging are derived 
from dyes, such as Congo red (CR) and thioflavin-T (Th-T), which have been used for 
fluorescent staining of Aβ plaques in postmortem AD brain sections 173, 174. Two analogues of 
Th-T; [11C]PIB175,176 and [11C]AZD2184177,178 have been used for clinical trials in AD 
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patients. However, due to short half-life of 11C, alternative 18F-labelled ligands with longer 
half-lives have undergone clinical trials such as a PIB derivative [18F]flutemetamol (3-[18F]F-
PIB),179,180 AZD2184 derivative [18F]AZD4694,181 pegylated stilbene and styrylpyridine 
derivatives, [18F]florbetaben (BAY 94-9172)182-184 and [18F]florbetapir (AV-45),184,185 
respectively. At present, medications used for treating moderate to severe AD can provide 
temporary relief from symptoms but no outcome with a strong disease-modifying effect.186,187 
Inhibition of the Aβ peptides formation, thus, emerged as a potential therapeutic approach. To 
identify BBB, penetrable small molecule drugs such as small peptides that interfere with Aβ 
peptide interactions, which are expected to prevent and/or cure these diseases, appear 
attractive. In this thesis, three small 12-mer D-enantiomeric peptides, specific to amyloid 
plaques (Aβ1-42) peptides of AD, were selected to observe the BBB penetration properties for 
diagnosis and potential therapy for AD. 
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2 AIMS 
 
The overall aim of the thesis was to develop novel fluorine-18 and carbon-11 labelled 
PET radioligands for two different important molecular targets: beta cell mass (BCM) for 
imaging diabetes related health problems and amyloid plaques for imaging Alzheimer’s 
disease (AD). 
 
The specific aims of the thesis were as follows: 
 
1. Development of novel radioligands for visualising endogenous BCM with the 
following sub-aims: 
a. Radiolabelling of [18F]FE-DTBZ-d4 (targets VMAT2), using fluorine-18 
for imaging beta cells by PET and to compare its in vitro and in vivo 
binding characteristics with the non-deuterated analogue [18F]FE-DTBZ.   
b. Radiolabelling of [11C]AZ12504948 (targets glucokinase), using carbon-11 
for visualising both liver and pancreatic beta cells by PET, as well as to 
evaluate in vitro and in vivo characteristics.    
c. Radiolabelling of a ligand targeting GPR44, AZ compound X, using 
carbon-11 and tritium for beta cell imaging by PET and to evaluate in vitro 
binding using autoradiography in human and rat pancreatic tissue slices.  
 
2.  Radiolabelling and in vitro evaluation of 18F-labelled D-peptides for visualising 
amyloid (Aβ) plaques in human brain tissue slices by autoradiography.  
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3 MATERIALS AND METHODS  
 
A brief summary of the general experiments and methods used during this thesis work 
are described in this section. However, for the complete experimental details, the reader is 
referred to the copies of the full papers and manuscripts that follow.  
 
3.1 RADIOCHEMISTRY 
 
Both radionuclides carbon-11and fluorine-18 were produced from a GE PETtrace 
cyclotron (GE Uppsala, Sweden) using 16.4 MeV protons. All the gases used for positron 
emitting isotope production were purchased from AGA Gas AB (Sundbyberg, Sweden). 
 
3.1.1 Production of [11C]methyl iodide ([11C]CH3I) 
 
Carbon-11 was produced by proton bombardment of nitrogen gas via the 14N(p,α)11C 
nuclear reaction. The primary precursor [11C]CH4 was produced from the mixture of target 
gas in nitrogen (N2) with 10% hydrogen (H2) of scientific grade purity (99.9999%). 
Throughout this thesis, [11C]CH4 was further converted to the secondary precursors, 
[11C]CH3I and [11C]CH3OTf using an online procedure. An aluminium target (78 mL) body 
was used with Havar foils (25 µm), where the target body was cooled using water and the foil 
using helium (He), respectively. The gas mixture was purified using gas purifier (All PureTM 
Alltech) prior to entering the target body to remove any traces of stable carbon-12.  
 [11C]CH3I, was produced from [11C]CH4 following previously published method67. In 
short, [11C]CH4 was transferred from the cyclotron to the dedicated methyl iodide synthesiser 
(methane system, DMA, Stockholm, Sweden) by Helium pressure (500 mL/min) and passed 
through a phosphorous pentoxide (P2O5) trap to remove traces of ammonia and water 
produced during the nuclear reaction. After passing through P2O5 trap, [11C]CH4 was trapped 
in a Porapak Q trap with liquid N2, which was purged with He to remove any unreacted target 
gases. Following collection, [11C]CH4 was released from the Porapak Q trap by heating with 
pressurised air into a recirculation system via He flow. The recirculation system consisted of 
a micro diaphragm gas pump (NMP830KVDC, KNF Neuberger, and Freiburg, Germany), 
quartz tube containing iodine and ascarite, three ovens, as well as a Porapak Q trap. The 
[11C]CH4 was first pumped to the quartz tube, where it was mixed with vapour of iodine 
crystals at 60°C (1st oven), and then the radical reaction occurred in the reaction chamber at 
720°C (2nd oven) to produce [11C]CH3I. Produced [11C]CH3I was trapped at RT to Porapak Q 
 20 
 
trap, and the excess amounts of iodine and by-product hydroiodic acid (HI) were trapped on 
ascarite (sodium hydroxide coated silica trap). The unreacted [11C]CH4 was recirculated for 
3–4 min to reach the maximum amount of [11C]CH3I in the Porapak Q trap (Figure 5). 
[11C]CH3I was further released from the Q trap by heating the homemade oven (3rd Oven) at 
180°C; subsequently, it was trapped in a suitable solvent or reaction mixture where the 
radiosynthesis i.e. methylation reaction, HPLC purification and formulation took place. The 
preparation of [11C]CH3I was ready for use within 10–11 min from the end of radionuclide 
production (Figure 5). 
        
Figure 5.  Flow chart for production of [11C]CH3I from in-target produced [11C]CH4 via gas phase iodination67.  
 
3.1.2 Production of [11C]methyl triflate ([11C]CH3OTf) 
 
Carbon-11 labelled [11C]CH3OTf was produced from [11C]CH3I, following previously 
described method.73,188 Produced [11C]CH3I was passed in a stream of He gas through a soda-
glass column (i.d: 3.7 mm; length 150 mm; oven temperature 165°C) containing silver 
triflate-impregnated graphitized carbon. The formed [11C]CH3OTf was trapped in appropriate 
solvent containing precursor material. 
 
3.1.3 Radiosynthesis, purification and formulation of 11C-radiopharmaceuticals 
 
The methylation reaction was performed in a fully automated custom built synthesis 
module (Scansys, Copenhagen, Denmark), where a PC programme is developed for the 
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control and programming of the system. The operator gets running information during the 
synthesis. During the entire process, the radioactivity was monitored using GM radio 
detectors. The reagents and solution used during the synthesis were placed in a clean air 
atmosphere. Radiosynthesis, purification and formulation of the final product took place 
under HEPA filtered air.  
Radioligand [11C]AZ12504948 (Paper II) and  [11C]AZ compound X (Paper III)  
were synthesised by O-methylation and S-methylation, respectively, using [11C]CH3I as 
methylating agent in one step. [11C]AZ12504948 was obtained by trapping [11C]CH3I at room 
temperature in a reaction vessel containing the precursor AZ12555620 (1.0 mg–1.6 mg, 2.16 
µmol–3.45 µmol) and freshly powdered solid potassium hydroxide (KOH) (10–13 mg, 178 
µmol–232 µmol) in dimethylsulfoxide (DMSO) (300 µL). After end of [11C]CH3I trapping, 
the reaction mixture was diluted with sterile water (500 µL) before injecting to the built-in 
high performance liquid chromatography (HPLC) system for purification of the labelled 
compound.   
[11C]AZ Compound X was synthesised by trapping [11C]CH3I at room temperature in 
a reaction vessel containing the precursor (1.0 mg–2.0 mg, 2.48 µmol–4.95 µmol) in 
dimethylformamide (DMF) (300 µL). After end of [11C]CH3I trapping, the reaction mixture 
was heated at 70°C for 5 minutes. The reaction mixture was diluted with sterile water (500 
µL) before injecting to the built-in HPLC system for the purification of the labelled 
compound. 
The chromatographic process was monitored in real time by means of UV detector 
and GM radio detector; furthermore, the HPLC column was scanned continuously by means 
of an extra GM radio-detector. After collecting the pure fraction of the corresponding 
radioligand, evaporation of the mobile phase was performed continuously online by stream of 
He using a carburetor. The labelled product was accumulated in the carburetor spiral, which 
was heated to moderate temperature (80°C), while the mobile phase was evaporated off. The 
HPLC system consisted of a pump (Gilson 304), an automated sample injector (Gilson 234 
autoinjector) and an ACE column (RP C18, 10 × 250 mm, and 5 µm). The formulation of the 
final product was accomplished by flushing the spiral with sterile phosphate buffer saline 
(PBS) and followed by filtration through a sterile filter (0.22 µm; Millipore, Sweden) into a 
sterile vial to get pyrogen free solution before applications. Self-cleaning routines of the auto-
sampler syringe, HPLC system, evaporator and tubing were executed, before and after the 
synthesis. All the running information during the synthesis was printed out after the 
completion of the synthesis.  
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3.1.4 Production of fluorine-18 
 
Fluorine-18 fluoride, [18F]F-, was produced from bombardment of 18O-enriched 
water ([18O]H2O), using the 18O(p, n)18F nuclear reaction from high pressurised silver 
target189. Produced [18F]F- was transferred to the dedicated hot cell with He pressure and 
isolated from [18O]H2O to a pre-conditioned [i) 10 mL 0.5 M K2CO3 solution ii) 15 mL 
water (18 MΩ)] SepPak QMA light anion exchange cartridge (Waters). Trapped [18F]F- was 
eluted from the QMA cartridge with QMA eluent (1.5–2.0 mL), which consisted of a 
mixture of K2CO3, Kryptofix2.2.2. (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo-
[8.8.8.]hexacosane-K2.2.2.) in water and acetonitrile, via N2 flow to a reaction vessel190. The 
QMA eluent was evaporated to dryness at 160°C under continuous N2 flow to form a dry 
complex of [18F]F- /K2CO3/K2.2.2,. and the residue was cooled to RT. The preparation of dry 
complex, [18F]F- /K2CO3/K2.2.2., was ready to use within 20–21 min after the end of 
radionuclide production (Figure 6). 
  
3.1.5 Radiosynthesis, purification and formulation of 18F-radiopharmaceuticals 
 
The 18F-radioligands synthesis (Papers I and IV) including HPLC purification, SPE 
isolation, as well as formulation of the final product took place in a semi-automatic 18F-
synthesis module (FIA-1 DMA, Figure 6). All valves, temperatures (R1 and R2) and radio-
detector output were possible to control or monitor using a touch screen. Flow of N2 gas was 
controlled by a needle valve and was followed by the flow metre, which was situated outside 
and inside of the hot cell, respectively. 
In paper I, precursor, 1-bromoethyl-2-tosylate-d4 (BrEtOTs-d4, 15 µL) was dissolved 
in aprotic polar solvent o-DCB (700 µL) and mixed with dry complex of fluoride, [18F]F- 
/K2CO3/K2.2.2 to synthesise the prosthetic group [18F]fluoroethylbromide-d4, ([18F]FEtBr-
d4). The reaction mixture (RM) was heated at 160°C for 10 min to produce crude 
[18F]FEtBr-d4, which was purified by fractional distillation and collected in a second vial 
containing desmethyl-DTBZ precursor (2.0–2.5 mg, 6.55–8.19 µmol), sodium hydroxide (15 
µL, 5M) in DMF (500 µL). The vial was placed in the 2nd reactor (R2 in Figure 6), and the 
RM was heated at 110°C for 5 min to produce crude [18F]FE-DTBZ-d4. 
In paper IV, prosthetic group N-succinimidyl-4-[18F]fluorobenzoate, [18F]SFB, was 
synthesised following the previously described method after modifications191, 192. The 
precursor 4-trimethylammoniumbenzoate trifluoromethanesulfonate (1) (5.0 mg, 20 mmol) in 
anhydrous MeCN (1 mL) was added to the dry [18F]F-/K2CO3/K2.2.2 complex, and the RM 
was heated at 90°C for 10 min to produce ethyl-4-[18F]fluorobenzoate ([18F]2), which was 
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used for the next reaction without further purification. [18F]2 was treated with 
tetrabutylammonium hydroxide (TBAH) (13 μL, 1 M in water) in 0.2 mL MeCN by heating 
at 120°C for 3 min to produce 4-[18F]fluorobenzoic acid salt ([18F]3). The mixture was dried 
azeotropically using MeCN (1 mL) at 160°C under continuous N2 flow to remove excess 
water from the addition of the aqueous solution of TBAH. The RM was cooled to 40°C, and a 
solution of the reagent N,N,N,N-tetramethyl-O-(N-succinimidyl)uronium hexafluoro- 
phosphate (HSTU) (12 mg, 33 mmol) in MeCN (1 mL) was added to [18F]3 and heated at 
90°C for 5 min to produce [18F]SFB, which was purified by semi-preparative HPLC followed 
by SPE isolation (HLB 60 mg) before use in the next step. Pure [18F]SFB was eluted with 
MeCN (~800 µL) from the SPE and used for the radiolabelling of [18F]D-peptides, 
([18F]ACI-87-F, [18F]ACI-88-F and [18F]ACI-89-F). In a solution of [18F]SFB (200 μL ~ 900 
MBq) in MeCN, precursor peptides (1.2 mg) in borate buffer (0.5M, pH 8.8; 150 μL) solution 
were dissolved and kept at RT for 10 min to produce crude [18F]D-peptides. Three [18F]D-
peptides were purified using analytical HPLC column (RP C18, 3.9×300 mm, 10 µm, 
Waters). The radiosynthesis and purification of [18F]D-peptides were performed in another 
hot cell, which is not included in Figure 6. 
 
 
 
Figure 6. Flow chart of production of both one step (only one reactor R1 is used) and two steps (both reactors 
R1 & R2 are used) fluorine-18 labelled radiopharmaceuticals, purification and formulation. 
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After the reaction, the crude reaction mixture was cooled to RT and was injected 
manually to the built-in HPLC purification system (Figure 6). The HPLC system consisted of 
a µ-Bondapak column (RP C18, 7.8×300 mm, 10 µm, Waters) and a UV detector in series 
with a GM tube. The pure fraction of the corresponding 18F-radioligand was collected in a 
bottle containing water (40–50 mL) for dilution, which was continuously passed through a 
pre-conditioned SPE (tC18 plus) cartridge [i) ethanol (10 mL) and ii) sterile water (10 mL)] 
by stream of N2 gas for isolation. SPE was washed by water (10 mL) using the manual 
syringe which was positioned outside of the hot cell. The formulation of the final product was 
accomplished by flushing the SPE with ethanol (<10%) and sterile PBS solution and 
collected in a sterile vial (Figure 6). All formulated 18F-labelled radioligands were filtered 
through a sterile filter (0.22 µm; Millipore, Sweden) into a sterile vial to get pyrogen free 
solution before applications. The aseptic work was performed in a laminar air flow 
workstation (LAFW). 
 
3.2 QUALITY CONTROL OF 11C AND 18F LABELLED 
RADIOPHARMACEUTICALS 
 
The radiochemical purity, identity and stability of 11C and 18F labelled 
radiopharmaceuticals were identified using analytical HPLC. The HPLC system consisted of 
RP analytical column, Merck-Hitatchi L-7100 Pump, L-7400 UV detector in series with a 
radioactivity detector (β-flow; Beckman, Fullerton, CA) for radioactivity detection. The 
identity of 11C and 18F labelled radiopharmaceutical(s) was confirmed by co-injection of the 
radiopharmaceutical(s) with its unlabelled reference standard, where the retention time of the 
radiopharmaceutical(s) was compared to that of the unlabelled reference standard. The 
stability of the radiopharmaceutical(s) was tested at different time intervals: 30, 60, 90, 120 
minutes after end of radiosynthesis.  
 
3.3 SPECIFIC RADIOACTIVITY (SRA) DETERMINATION 
 
The specific radioactivity (SRA) of all radiopharmaceutical(s) was measured using 
analytical HPLC system from Merck-Hitachi with D-6200A pump, L-4000 UV detector and 
D-6000 interface. SRA was calibrated for UV absorbance response per mass of ligand and 
calculated as the radioactivity of the radioligand (GBq) divided by the amount of associated 
carrier substance (µmol). Each sample (radioligand after decay) was analysed three times and 
compared to a reference standard (known concentration) which was also analysed three 
times, by taking same amount of the sample by the auto-sampler of the HPLC system. 
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3.4 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (LC-MS/MS) 
ANALYSIS 
 
The structure of 11C and 18F radiopharmaceuticals were further confirmed by 
comparing LC and MS fragmentation pattern of the reference standards and that of the carrier 
of the corresponding nonradioactive compounds. LC-MS/MS analysis was performed using a 
Waters AcquityTM ultra performance LC system connected with a Micromass premierTM 
Quadrupole time of flight (TOF) mass spectrometer (Waters, Milford, MA, USA). LC was 
performed using a Waters Acquity UPLCTM BEH column (C18, 2.1 × 50 mm, 1.7 µm 
particle size) kept at 50°C. The mobile phase consisted of 0.1% formic acid in water (A) and 
0.1% formic acid in ACN (B). Samples were analysed using a linear gradient at a flow rate of 
0.5 mL/min. The MS was operated in positive electrospray ionization (+ESI) mode, with the 
following settings: capillary voltage 3.0 kV; cone voltage 35 V; source temperature 100°C; 
dissolvation temperature 400°C and collision energy 20 eV. The formulated product, 11C and 
18F radiopharmaceuticals, was analysed after radioactive decay without further dilution.  
 
3.5 IN VITRO AUTORADIOGRAPHY  
 
Biopsies from human pancreas and liver of healthy subjects and type 2 diabetic (T2D) 
subjects were collected from deceased human donors (Paper II-III). The use of human tissue 
was approved by the Uppsala Ethical Review Board (Dnr 2015-401; # 2011/473, #Ups 02-
577) and tissues obtained from Uppsala Biobank. The biopsies were frozen to -80°C and 
processed into 20 µm slices. Slides were kept at -20°C until use. 
AD human brain (Paper IV) was obtained from the Alzheimer Brain Bank of the 
University of Szeged, Hungary. The age matched control human brain was obtained from the 
Institute for Forensic Medicine, Semmelweis University, Budapest, Hungary. Brains had 
been removed during a forensic autopsy and were handled in a manner similar to that 
previously described193, 194. Fresh frozen whole hemisphere brain slices (100 µm) was 
prepared. Ethical permissions for the study were obtained from the relevant university ethical 
boards. Slides were kept at -20°C until use.     
In paper II, to study radioligand binding properties of different tissues, pancreas 
[healthy (n=1),  T2D (n=2)] and liver [healthy (n=1)], slices were incubated in different 
concentration (0.05-1.0 nM) of the radioligand, [11C]AZ12504948, in 50 mM TRIS HCl 
containing 5 mM D-(+)-glucose (Sigma-Aldrich, St Louis, MO, USA) and 0.4 mg/mL β-
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cyclodextrin (Kleptose HPB, original formulation 300 mg/mL, Apoteket, Umeå, Sweden) for 
40 minutes at RT. Non-displaceable binding was assessed by adding excess amount of (11-13 
µM) of unlabelled AZ12504948. Tissue slices were washed twice for two minutes in 50 mM 
TRIS HCl containing 5 mM D-(+)-glucose at RT to remove excess tracer, followed by a brief 
wash in distilled water and then dried for 5 min on a hot-plate (37°C). The slices were then 
exposed to a phosphor-imager screen (Amersham Biosciences, Uppsala, Sweden) for 4-6 
hours, scanned using a Phosphorimager SI (Molecular Dynamics, Sunnyvale, CA, USA) and 
analysed using ImageQuant (Molecular Dynamics, Sunnyvale, CA, USA). The affinity for 
the specific binding was expressed as the dissociation constant Kd, determined by GraphPad 
Prism 5 (San Diego, CA, USA). 
In paper III, sections of pancreas from non-diabetic (n=6) and T2DM (n=6) as well as 
from Sprague Dawley rats (n=4) for ARG experiments using the PET ligand [11C]AZ 
compound X, were pre-incubated in 100 mL 50 mM PBS (pH 7.4) for 10 minutes. Then, 
radioactivity corresponding to 1 nM [11C]AZ Compound X (n=3) was added, and sections 
were incubated with the radioligand for 30 min at RT. Non-displaceable binding was assessed 
in a separate assay, by co-incubation with 20 µM of the GPR44 antagonist AZ Compound Y. 
Autoradiography (ARG) experiments using tritiated ligand, [3H]AZ Compound X, were 
performed by following similar procedure as described for [11C]AZ Compound X, except all 
sections were (healthy, n=3 and rats n=3) incubated with 1 nM [3H]AZ Compound X at RT 
for 3 hours. Following incubation, tissue sections were washed 3 times for 2 minutes in 50 
mM PBS at 4°C. The sections were dried and exposed to phosphor-imager screen for 40 
minutes with [11C]AZ Compound X and 90 hours with [3H]AZ Compound X. 
In paper IV, ARG was performed on fresh frozen whole hemisphere brain slices. The 
incubation buffer consisted of TRIS HCl (50 mM) including NaCl (120 mM), KCl (5 mM), 
CaCl2 (2 mM) and MgCl2 (1 mM), as well as 10 µM pargylin and 0.3% bovine serum 
albumine, pH 7.4. The brain slices were incubated with the buffer at radioligand 
concentration of 0.02 MBq/mL with [18F]-peptides for 90 min, at RT. The measurements 
were done in duplicates. The slices were then rinsed with a buffer consisting of TRIS HCl (50 
mM), three times for 5 min each at 4°C; followed by dipping in ice cold distilled water.  
The slices (Papers III-IV) were scanned using a Cyclone Plus Phosphor imager (Perkin 
Elmer) at 600 dpi in case of [11C]AZ Compound X and [18F]peptides, as well as Fujifilm 
BAS-5000 phosphor imager (Fujifilm, Tokyo, Japan) in case of [3H]AZ Compound X. The 
images were analysed using ImageJ (NIH). Specific binding was defined by subtracting non-
displaceable binding from total binding. 
 
 27 
 
3.6 HOMOGENATE TISSUE SATURATION BINDING  
 
Isolated endocrine and exocrine tissues from human pancreas195 were homogenised by 
using a polytron tissue homogeniser (Polytron® PT 3000, Kinematica AG, Littau, 
Switzerland) and incubated in TRIS [tris(hydroxymethyl)aminomethane] (50 mM) solution. 
The tissue homogenates (0.5–6 mg/mL) were incubated in 1 mL TRIS (pH 7.4) with different 
concentrations of specific 11C- or 18F-radioligand around an expected Kd. Aliquots of the 
homogenates were stored at -80oC until used. All homogenised endocrine and exocrine 
samples were incubated separately for 30 to 60 min at RT with radioactivity and then moved 
onto a Brandel 1.2 µm Whatman filter (pre-treated with 0.05% polyethylenimine or TRIS) by 
M-48 cell harvester (Brandel, Gaithersburg, MD, USA). The filter was washed four times 
with 3 mL TRIS (RT) and measured in a well-counter (Uppsala Imanet AB, GE Healthcare, 
Sweden). Tissue samples and references were prepared in triplicates and filter binding 
controls in duplicates. Non-displaceable binding was accessed by adding unlabelled cold 
ligand in high concentration (10–20 µM) to the incubation buffer. The specific binding was 
calculated by subtracting the non-specific binding from the total binding, and the endocrine-
to-exocrine binding ratio was calculated. Tissue protein content (mg protein/sample) was 
assessed by a BioRad Protein Assay (BioRad, Hercules, CA, USA), and absorbance was 
measured with an EL808 microplate reader (BioTek, Winooski, VT, USA). The Binding 
Potential (BP), (Bmax/Kd), was determined by non-linear regression (Paper I). 
 
3.7 PET/CT IN PIG AND NONHUMAN PRIMATE (NHP) 
 
Swedish Landrace piglets were used in this thesis work and were housed under the 
proper lab conditions. All procedures were approved by the local ethical committee for 
animal experimentation (Uppsala, Sweden; ethical permit Dnr C 245/8) and performed in 
accordance with local institutions and Swedish national rules and regulations. Piglets were 
anesthetised by using ketamine and morphine and they were intubated and placed on a 
ventilator. The anaesthesia was maintained by 2.5% sevofluran. Normoglycemia was 
confirmed by determining blood glucose content (4.4 to 7.6 mM) using an i-STAT analyser 
(CG8+cartridges, Abbot Point-of-Care, Inc, Princeton, NJ, USA). Animals were administered 
5.9–20.6 MBq/Kg of the radioligand intravenously (baseline scan, n=3), and the blocking 
study (n=2) was performed by co-administration with 1.5 mg/kg unlabelled ligand 
formulated in a mixture of sterile ethanol (30%) in propylene glycol and sterile PBS (3:5) to 
study the specific binding. The pharmacological effect was analysed by comparing decrease 
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in plasma glucose levels before and 90 min after unlabelled ligand administration. The 
biodistribution as well as kinetics of the radioligand were studied by a Discovery ST PET/CT 
scanner (GE, Milwaukee, WI, USA) for 90 min with a dynamic sequence of (30 sec frames x 
4, 1 min frames x 3, 3 min frames x 5, 5 min frames x 14). The CT scans were acquired for 
attenuation correction. Arterial (Paper I) and venous (Paper II) blood samples were acquired 
throughout the study and centrifuged at 3500 rpm for 5 minutes to separate the plasma. Both 
whole blood and plasma were measured for radioactivity using the well counter. 
Cynomolgus monkeys (Macaca fascicularis), housed in the Astrid Fagraeus laboratory, 
Karolinska Institutet, Solna, Sweden. The experiment with the monkey was approved (N 
399/08) by the Animal Ethics Committee of the Swedish Animal Welfare Agency and was 
performed according to the Guide for the Care and Use of Laboratory Animals196. One 
cynomolgus monkey (male, 5.4 kg) was used in this thesis (Paper II); the monkey handling, 
anaesthesia and PET/CT procedure were under the control of research nurses. The 
anaesthesia was induced by intramuscular injection of ketamine hydrochloride and 
maintained by intravenous infusion of ketamine hydrochloride and xylazine hydrochloride. 
The body of the monkey was immobilised using a vacuum pad. Blood glucose content was 
assessed by using an i-STAT analyser (CG8+cartridges, Abbot Point-of-Care, Inc, Princeton, 
NJ, USA). The monkey was positioned in order to view the abdomen in the field of view 
(FOV). The whole body PET measurement was performed for 120 min (3-min frame x 3, 4-
min frame x 3, 5-min frame x 3, 6-min frame x 14) in a PET/CT scanner (Siemens Biograph 
64). Baseline and blocking studies were accomplished by administration of 34 and 37 
MBq/kg of the radioligand, respectively. The blocking study was performed by co-
administration with 0.5 mg/kg unlabelled ligand formulated in a mixture of sterile ethanol 
(30%) in propylene glycol and sterile PBS (3:5).  
Tissue uptake and kinetics for both pig and NHP were obtained by delineating VOIs on 
partially summed PET images assisted by CT morphology. All image analysis was performed 
with the PMOD software (PMOD Technologies Ltd, Zürich, Switzerland). Measurements of 
the uptake were analysed by using standardised uptake value (SUV), which is the regional 
tissue radioactivity concentration normalised for the injected dose and body weight of the 
subject. 
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4 RESULTS AND DISCUSSION 
 
4.1 RADIOLABELLING AND BIOLOGICAL EVALUATION OF DEUTERATED  
 [18F]FE-DTBZ-D4 (PAPER I) 
 
Dihydrotetrabenazine (DTBZ) is highly specific for the vesicular monoamine 
transporter type 2 (VMAT2), and VMAT2 is co-localised with insulin in islets but is not 
detectable in exocrine pancreas197. [11C]-(+)-DTBZ has been shown to be a BCM biomarker 
with a potential to distinguish between healthy and diabetic subjects longitudinally, however, 
with some difficulties161. Development of 18F-labelled DTBZ derivative such as 
[18F]fluoroalkyl-DTBZ198-200 and [18F]fluoroepoxide-DTBZ201 appeared in order to get 
improved version of [11C]DTBZ as BCM biomarker, since 18F has longer half-life and higher 
electronegativity compared to 11C. The radioligand, [18F]FE-DTBZ, was investigated by our 
group in 2010 as a first attempt for the development of BCM biomarker; at that time, we 
found that the radioligand was metabolised extensively by in vivo defluorination in a large 
piglet model202. In order to improve the in vivo stability, deuterated analogue of [18F]FE-
DTBZ was designed, which could improve the VMAT2 uptake in BCM as well as in central 
nervous system (CNS). The in vitro and in vivo results of deuterated FE-DTBZ-d4 were 
compared retrospectively to that of the non-deuterated FE-DTBZ radioligand.  
 [18F]FE-DTBZ-d4 was synthesised in two steps via indirect fluorination strategy 
following the previously described method, with slight modifications203 (Scheme 1). In the 
first step, the prosthetic group [18F]FEtBr-d4 was synthesised by aliphatic nucleophilic 
substitution reaction via SN2 mechanism, where the tosylate (-OTs) leaving group of the 
precursor BrEtOTs-d4 was substituted with [18F]fluoride and formed [18F]FEtBr-d4. In the 
second step, the final 18F-product [18F]FE-DTBZ-d4, was synthesised via the coupling of the 
[18F]fluoroethyl-d4 moiety to the 9-O-desmethyl-DTBZ precursor. Purification of [18F]FEtBr-
d4, was performed by distillation and isolated in good yield. The conversion of the second 
step i.e. conversion of [18F]FEtBr-d4 to [18F]FE-DTBZ-d4 was >70% based on analytical 
HPLC analysis. Determination of pH and volume, and visual inspections of the final 
formulated product were performed before releasing it for the QC analysis. The total time of 
the radiosynthesis, including purification and formulation, was 100±20 min after the end of 
18F-production. [18F]FE-DTBZ-d4 was produced in good and reproducible radiochemical 
yield; 1.7 to 3.0 GBq of the pure product was obtained from 20 to 25 min of proton 
bombardment with beam current of 35 μA. The radiochemical purity was >98% up to 2 hours 
after EOS, and QC analysis was performed before releasing the radioligand for applications 
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such as in vitro ARG, homogenate binding and in vivo PET/CT studies. The structure of the 
radioligand was further confirmed by comparing the LC-MS/MS data of both reference 
standard and carrier of the [18F]FE-DTBZ-d4 (after decay). The retention time of the 
formulated product and the fragmentation pattern of the parent peak were identical to that of 
the reference standard. SRA of [18F]FE-DTBZ-d4 was high, with a range of 192–529 
GBq/µmol after EOS.     
           
                  
 
Scheme 1.  Synthesis of [18F]FE-DTBZ-d4 using [18F]FEtBr-d4 as alkylating agent in two steps.  
 
The in vitro BP ratio of deuterated [18F]FE-DTBZ-d4, in human endocrine and 
exocrine tissue homogenate was slightly higher than that of the non-deuterated [18F]FE-
DTBZ analogue (16 vs 11) i.e. greater tissue discrimination. The in vivo PET/CT piglet 
studies (n=3) showed homogeneous uptake of the radioligand in the pancreas with no 
difference in the head, tail and body of the tissue. The average uptake of the radioligand, 
expressed in SUV, reached 2.64 shortly after the I.V. administration with a SUV of 1.8 after 
90 min, which was comparable to that of the non-deuterated version. Notable accumulation 
was observed in the liver and spleen with faster washout kinetics than the pancreas. Apart 
from the excretion through the bile system, excretion through the kidney, bladder and urethra 
was also observed (Figure 7a). The main goal of the study was achieved by observing 
reduced bone uptake of the deuterated radioligand in vivo, where it showed moderate uptake 
(SUV 1.4) of radioactivity with no further accumulation (Figure 7b), whereas the bone uptake 
increased linearly with time for the non-deuterated analogue (SUV of 3.1 at 90 min). 
However, there was no significant difference observed in specific VMAT2 binding uptake in 
the pancreas in in vivo PET/CT studies, even though more native [18F]FE-DTBZ-d4 was 
present in blood plasma.  
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 Figure 7a    Figure 7b 
Figure 7.  (7a): Delineation of pancreas (red), spleen (green) and parts of the anterior and posterior hepatic 
segments (black) exemplified on a transaxial PET/CT fusion image (a). The average dynamic uptake of [18F]FE-
DTBZ-d4 in pancreas and other abdominal tissues from 4 different piglets (b). Excretion through the biliary 
system is the fate of a majority of the tracer and its metabolites (c), but there is also elimination of tracer by urine 
(d).   (7b): 3D Maximum Intensity Projection (MIP) 90 minutes after administration of (a) [18F]FE-DTBZ-d4, 
low accumulation in bone structures indicates low levels of free [18F]F-. (b) non-deuterated [18F]FE-DTBZ, high 
accumulation in bone structures due to higher levels of free [18F]F-. Colours indicate SUV 0 (black) to SUV 30 
(white). 
 
4.2 RADIOLABELLING AND BIOLOGICAL EVALUATION OF [11C]AZ12504948 
IN PANCREAS AND LIVER (PAPER II) 
 
Glucokinase (GK) is an enzyme predominantly present in the beta cells of the islets of 
Langerhans in the pancreas204 and hepatocytes in the liver205 and as a result, is a potential 
target for BCM visualisation. GK is regulated by a class of small molecules called 
glucokinase activators (GKAs). GKAs increase the enzymatic activity of GK upon binding to 
a hydrophobic pocket, thereby, stabilising the bound state between GK and its substrates206. 
The GKA mechanism of action offers a pharmaceutical target for control of hyperglycemia; 
therefore, GKAs have been a hot topic in drug development207, 208. 
A novel GKA radioligand, [11C]AZ12504948, was synthesised by O-
methylation using a combination of methylating agent [11C]CH3I, base KOH(s) and DMSO as 
solvent in one step at RT (Scheme 2). The solution of the aliphatic desmethyl precursor, 
AZ12555620, with freshly powdered KOH in DMSO, needed to be vortex for ten min to 
ensure formation of the alkoxide anion prior to labelling with [11C]CH3I. Besides DMSO, 
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DMF was also used as solvent for the reaction but did not result in the formation of the 
desired labelled product. Several bases such as sodium hydride (60% in oil), aqueous NaOH 
(5M and 0.5M), triethylamine, solid powdered K2CO3, KOH and NaOH were assessed; 
however, only NaOH(S) resulted in the desired labelled product. Reaction parameters such as 
temperature (RT-140°C), reaction time (1–15 min), amount of precursor used (0.2–1.6 mg) 
were also investigated. Heating the reaction mixture did not improve the yield but started the 
decomposition of the formed [11C]AZ12504948. It was observed that the radiochemical 
conversion of [11C]CH3I to the desired product [11C]AZ12504948 was dependent on the used 
concentration of the precursor. Further experiments were performed to optimise the RCY by 
using the identical reaction conditions but with variation in the amount of precursor 
AZ12555620 used. The RCY varied from 10%–85%, depending on the amount of the 
precursor (0.2 mg–1.6 mg), and the yield reached maximum when amount of the precursor 
was >1.0 mg.  
The total time of radiosynthesis including purification and formulation of the 
product was 28–30 min after end of the radionuclide production. The synthesis was highly 
reproducible, and the conversion of [11C]CH3I to [11C]AZ12504948 was >90% (based on 
analytical HPLC). It was possible to produce up to 3000 MBq of pure product from 30 min of 
proton bombardment, at beam current of 35 μA, for PET studies. The radiochemical purity 
was >98% up to 2 hours after EOS. The specific radioactivity ranged from 582–2350 
GBq/µmol after EOS. The precursor, AZ12555620, had two active sites for alkylation, which 
potentially could be radiolabelled by 11C-methylation, either at the N-position of the 
secondary amide or at the O-position of the aliphatic hydroxyl group. The goal was to label at 
O-position with 11C to get the desired product [11C]AZ12504948 (Scheme 2). The position of 
the methylation, O-alkylation instead of N-alkylation, was confirmed by comparing the LC-
MS/MS fragmentation of the reference standard and precursor compound.  
 
 
 
           Scheme 2. Radiosynthesis of [11C]AZ12504948 via [11C]CH3I.  
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In vitro ARG saturation binding study in human tissues showed around 50% 
specificity (47.3±4.1%) to liver and low specificity (only 7.8%±3.6%) to pancreas from non-
diabetic human donors at sub-nanomolar concentration of [11C]AZ12504948. However, 
despite the low portion of specific receptor binding in the in vitro studies, we decided to 
perform additional studies using pigs to observe the bio-distribution of [11C]AZ12504948 in 
baseline condition and the specificity of [11C]AZ12504948 by performing blocking 
experiments (co-injection of cold ligand, 1.5 mg/kg). During the blocking experiments, 
pharmacological effect of the cold ligand (GKA), AZ12504948, was followed by measuring 
the blood glucose concentration, which decreased from 5.2 to 3.6 mM (measurement 1) and 
from 4.0 to 2.7 mM (measurement 2). The baseline studies demonstrated moderate uptake in 
the pancreas and slightly higher uptake in the liver following similar kinetics. In blood 
plasma, only 20–25% of the radioactivity was observed in the first 10 min and increased up to 
40% after 90 min during the scan. In the blocking studies, the pancreatic uptake was reduced 
by 24% and liver uptake by 15%, after 30–60 min. In blood plasma, around 70% of the 
radioactivity was observed after 90 min (Figure 8). 
In the non-human primate study (n=1), both baseline and blocking experiments 
were performed during the same day. In the baseline study, uptake in GK rich tissues such as 
pancreas and liver was higher in the monkey than in the pigs with similar bio-distribution 
pattern. In the blocking experiment, 0.5 mg/kg of the cold ligand (AZ12504948) was used, 
and the pharmacological effect of GK agonist was confirmed by a reduction in blood glucose 
concentration from 7.1 to 5.2 mM after 90 min. The uptake of the liver was reduced by 14% 
after 30–60 min post injection (p.i.), whereas no reduction was observed for pancreas after 
blocking (Figure 9).  
 
Figure 8. Tracer kinetics in liver, pancreas and blood plasma during baseline (n=3) and blocking scans (n=2) 
in pig. Values are expressed as SUV and given as means ± SEM. 
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Figure 9. Tracer kinetics in liver and pancreas during baseline (n=1) and blocking scans (n=1) in non-human 
primate. Values are expressed as SUV. 
 
The major route of excretion of the radioligand was through the bile system into the 
duodenum and large intestine, which could result in difficulty in detecting and separating the 
specific ligand-GK interactions in both the liver and pancreas. However, increased target 
specificity is required for further progress in GK imaging using PET radioligands in pancreas 
and liver based on this class of GK activators. 
             
4.3 RADIOSYNTHESIS AND IN VITRO EVALUATION OF [11C]/[3H]AZ 
COMPOUND X IN HUMAN PANCREAS (PAPER III). 
 
G-protein coupled receptor 44 (GPR44, also known as postaglandin D2 receptor 2) is a 
protein recently characterised as a highly beta cell specific surface target and absent from 
remaining islet cells as well as exocrine cells209. To generate a potential PET radioligand for 
visualising BCM in native pancreas, the GPR44 specific ligand, AZ Compound X, was 
selected and here radiolabelled with carbon-11 and tritium. The ligand was labelled using 
tritium, to validate and characterise the binding properties using high resolution in vitro ARG 
technique with human and rat pancreatic tissue. Similar in vitro binding properties were 
explored using the [11C]AZ Compound X in post-mortem human and rat pancreatic tissue 
slices. 
The radioligand, [11C/3H]AZ Compound X, was synthesised from the sodium salt of 
sulfinic acid precursor, in DMF using methylating agent [11C/3H]CH3I in one step (Scheme 
3). The radiolabelled product was formed as sulfone instead of sulfinate ester via S-alkylation 
instead of O-alkylation, which was in agreement with the Hard Soft Acid Base (HSAB) 
principle210. It has been shown previously that alkylation of sulfinate anion with hard 
alkylating agent results predominantly in ester formation, whereas soft alkylating agent such 
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as methyl iodide mainly results in the formation of sulfone211, which supported our findings. 
In case of [11C]CH3I, methyl carbonium ion (CH3+) is attached to a soft base Iodide (I-); thus,  
CH3+ acts as a soft  acid. Co-ordination of CH3+ with the soft base Sulphur (S) is preferable 
compared to the harder base Oxygen (O) present in the precursor molecule. When more 
reactive methylating agent [11C]CH3OTf was used for labelling, a major radiolabelled by-
product was formed. This did not co-elute with the reference standard in analytical radio-
HPLC, which can be explained by formation of O-alkylated sulfonate ester. However, the 
formed radiolabelled entity was not characterised.  
The conversion of [11C/3H]CH3I to the product, [11C/3H]AZ Compound X, was almost 
quantitative at this condition. The total time of the radiosynthesis was 28–30 min after EOB, 
including online HPLC purification and formulation (PBS). The synthesis was highly 
reproducible; it was possible to produce up to 2500 MBq of pure product from 30 min of 
proton bombardment at a beam current of 35 μA. The radiochemical purity of [11C]AZ 
Compound X was >99% up to 2 hours and >99% for [3H]AZ Compound X in formulation 
solution, even after 1 week of EOS. The SRA of [11C]AZ Compound X ranged from 900–
3000 GBq/µmol and for [3H]AZ Compound X was 2 GBq/µmol after EOS.  
 
 
 
Scheme 3. Radiosynthesis of [11C/3H]AZ Compound X via [11C/3H]CH3I. 
 
The ARG images using [11C]AZ Compound X in human pancreatic slices 
showed heterogeneous hotspots corresponding to islets of Langerhans in both healthy and 
T2DM subjects in contrast with rat pancreas, which has no GPR44 expression (used here as 
negative control). It was possible to almost completely block the binding to human pancreatic 
tissue in contrast with rat pancreatic tissue by co-incubation with 20 µM GPR44 antagonist 
AZ Compound Y. The enrichment in islet hotspots was >7 times higher than the exocrine 
background in tissues from both healthy and T2DM subjects (Figure 11). Comparable in vitro 
ARG results were found using [3H]AZ Compound X (Figure 12). In vitro binding of [11C]AZ 
Compound X to pancreatic tissue homogenates showed higher specificity towards islets than 
exocrine tissue. The specific binding was 8–20 times higher in islets of Langerhans than in 
exocrine preparations (Figure 13). No experiments were performed using tissue homogenates 
with the tritium labelled ligand. The specificity of the radioligand [11C]AZ Compound X 
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towards islets was confirmed by insulin staining, where most of the hotspots were co-
localised with insulin (Figure 14). 
 
 
 
Figure 11: In vitro autoradiography of [11C]AZ Compound X, Specific binding in pancreas from healthy human 
subjects (A), subjects with T2D (B) and healthy rat (C).The pancreatic binding of tracer is displaceable in human 
but not in rat (D), and the human pancreatic binding is concentrated to the islet of Langerhans (E). 
 
Figure 12: In vitro autoradiography total binding in 
pancreas by 1 nM [3H]AZ Compound X incubated 
for 3h from healthy human subjects (A) and healthy 
rat (B). 
Figure 13: The islet-to-exocrine specific binding 
ratio was close to 20 at nanomolar concentration of 
radioligand [11C]AZ Compound X. 
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Figure 14.  Autoradiogram (A) and insulin staining (B) of consecutive section of non-diabetic human pancreas 
show correlation of the [11C]AZ Compound X tracer uptake to beta cells. 
 
The in vitro binding properties of GPR44 radioligand, [11C]/[3H]AZ Compound X, in 
human pancreas and rat pancreas showed very promising results. These results motivate its 
further evaluation as a PET radioligand, in a preclinical setting. 
 
4.4 FLUORINE-18 LABELLING OF THREE NOVEL D-PEPTIDES WITH 
[18F]SFB AND EVALUATION BY WHOLE-HEMISPHERE HUMAN BRAIN 
SLICES AUTORADIOGRAPHY (PAPER IV) 
 
A mirror image phase display selection approach212 was used to find small size peptide 
(12-mer, a.a sequence = qshyrhispaqv, named D1) using amyloid peptide Aβ (1-42) as target. 
In vitro studies using D1-peptide labelled with fluorescence dye FITC demonstrated specific 
binding to Aβ plaques in brain tissue sections from former AD patients and did not bind to 
fibrillary deposits derived from other amyloidosis (which do not contain Aβ(1-42))213 in 
contrast with Congo red, which is known to bind to any amyloid and amyloid-like fibrils, 
regardless of their chemical identity213, 214. In vivo studies with FITC-D1 peptide in transgenic 
AD model mice confirmed high specificity to dense Aβ deposits (i.e. plaques), compared to 
diffuse Aβ deposits215. Moreover, D1-peptide showed properties in reducing Aβ cell toxicity 
and amyloid fibril formation216. All data taken together demonstrates that D1-peptide or 
derivative of D1-peptide might be suitable for use as a molecular probe for the detection of 
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amyloid plaques in living humans or animals for early diagnosis of AD or to search for 
compounds that are suitable for AD therapy or to monitor Aβ plaque load during disease 
progression. In this present work, D-enantiomeric a.a was selected, since D-enantiomeric 
peptides are known to be less protease sensitive and more resistant to degradation in 
animals217-219 than L-a.a.220-223. Therefore, D-peptides will be advantageous as a PET probe for 
visualising amyloid plaques in vivo. Three derivatives of D1-peptides were chosen as 
precursor and chemically constructed having a lysine (k) group for 18F-radiolabelling by 
conjugation of prosthetic group [18F]SFB.  
Unlabelled SFB and the triflate precursor (1) for the radiolabelling of [18F]SFB  were 
synthesised following previously published method, with good yield224, 225 (Scheme 4). 
[18F]SFB was synthesised in three steps in one pot via HPLC purification before using it for 
the next step (18F-peptide synthesis) based on the literature method, with modifications226, 227 
(Scheme 5). In our hands, purification of [18F]SFB using only cartridge was not good for the 
18F-peptide labelling. Probably, some unidentified nonradioactive by-products, which were 
not removed during SPE purification of [18F]SFB, affected the radiolabelling of the peptides. 
Dry complex of [18F]F-/K2CO3/K2.2.2 was isolated in a reaction vial to which the precursor (1) 
in acetonitrile was transferred. The aromatic nucleophilic substitution reaction took place 
under heating and [18F]2 was formed, followed by hydrolysis using base under heating, and 
[18F]3 was produced.  A solution of the reagent HSTU in acetonitrile was added to [18F]3, and 
[18F]SFB was produced under heating followed by purification on semi-preparative RP 
HPLC column. The fraction of [18F]SFB was isolated on a SPE cartridge and eluted by 
acetonitrile for use in the second step. The total time of [18F]SFB synthesis was 90 min from 
the EOB, and [18F]SFB was produced in good yield (up to 3600 MBq from 15 min of 
irradiation, 30–35 μA). The [18F]SFB was identified by analytical HPLC, comparing with the 
synthesised nonradioactive reference standard SFB. The radiochemical purity of [18F]SFB 
was >98%.   
 
 
 
                    Scheme 4. Synthesis of SFB (reference of [18F]SFB). 
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Scheme 5. Radiosynthesis of [18F]SFB via18F-fluoride ([18F]F-) by three steps in one pot. 
 
The references, 19F-peptides ([19F]ACI-87-F, [19F]ACI-88-F and [19F]ACI-89-
F), were synthesised in one step (Scheme 6) where precursor peptides were dissolved in 
borate buffer solution (pH~8.8) and excess amount of SFB in acetonitrile was added. The 
reference 19F-peptides were purified by analytical HPLC system using a gradient method with 
acidic condition. All 19F-peptides were unstable in the acidic mobile phase used during 
purification; therefore, purified peptide fractions were collected in a prefilled basic solution 
(adjusted with NaOH) in which the 19F-peptides were stable. Three 18F-peptides ([18F]ACI-
87-F or [18F]ACI-88-F or [18F]ACI-89-F) were radiolabelled using produced purified 
[18F]SFB in the first step. Reaction condition for labelling was similar as the condition used 
for reference peptide synthesis. The incorporation yield of [18F]SFB to the 18F-peptides was 
>80% in all synthesis. Crude 18F-peptides were purified by analytical HPLC system; in our 
hands, purification of peptides was not possible using semi-prep HPLC column. Pure fraction 
of 18F-peptides was loaded to a SPE cartridge and eluted using EtOH and formulated in PBS 
solution. The formulated 18F-peptides were filtered manually via a sterile filter (0.22 µm) and 
transferred to a sterile vial to get pyrogen free product before further use. Total time of 
synthesis was 40 min at the EOS of [18F]SFB. The identity and radiochemical purity of 18F-
peptides was confirmed by analytical HPLC, comparing with the unlabelled synthesised 
reference peptides (19F-peptides). The radiochemical purity of the formulated 18F-peptides 
was >98% and was found to be radiochemically stable for up to 3 hours. The specific 
radioactivity obtained from [18F]ACI-87-F was 16 GBq/µmol and 11 GBq/µmol, [18F]ACI-
88-F was 113 GBq/µmol and 9 GBq/µmol, [18F]ACI-89-F was 86 GBq/µmol and 27 
GBq/µmol. 
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Scheme 6. Radiosynthesis of [18F/19F]-peptides using the prosthetic group [18F/19F]SFB at RT. 
 
The in vitro autoradiographs of whole hemisphere human brain slices (coronal 
sections) of an AD patient and an age matched control (non-AD) demonstrated higher 
radioligand binding at the level of hippocampus. The average grey matter-white matter 
uptake ratios of the three D1 derivatives was also higher in AD brain than control brain slices, 
and [18F]ACI-88-F showed the best result (Figure 15 is an example of [18F]ACI-88-F). These 
promising in vitro data indicated their potential as imaging biomarkers for visualising 
amyloid plaques in the living brain.  
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Figure 15.Whole hemisphere coronal autoradiographs, using [18F]ACI-88-F as radioligand, brain of a 50-year- 
old female with AD (A) and a 54-year-old male control (B). Higher binding in the grey matter and in the 
hippocampus was observed in AD slice compared to the control (darker colour indicates higher radioligand 
uptake). Panels (C) and (E) represent the enlargements, indicated by the rectangular image boxes in panels (A) 
and (B). 
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5 SUMMARY OF FINDINGS  
 
The present thesis focused on development of small molecule PET probes for BCM imaging 
and development of peptide molecule (12-amino acid), PET probes, for Aβ plaque imaging in 
the brain. 
Firstly, a fluorinated analogue of the VMAT2 radioligand DTBZ was developed. In 
order to reduce the rate of in vivo defluorination of previously published radioligand, [18F]FE-
DTBZ, isotopic substitution of the four hydrogen atoms on the 18F-ethyl group with 
deuterium was performed and tested, both in vitro and in vivo by PET. [18F]FE-DTBZ-d4, 
was radiolabelled in two steps from optically resolved 9-O-desmethyl-(+)-DTBZ precursor 
using the prosthetic group, deuterated [18F]fluoroethylbromide [18F]FEtBr-d4, at O-position 
by nucleophilic alkylation reaction. The in vivo stability of the novel radioligand [18F]FE-
DTBZ-d4 has improved notably through the deuterium isotopic effect, since cleavage of C-D 
bond via enzymatic attack is more difficult to break than C-H bond. However, our findings 
suggest that [18F]FE-DTBZ-d4 is not a suitable PET radioligand for endogenous BCM 
imaging in pancreas due to high nonspecific interactions in vivo obscuring the islet signals. 
Secondly, carbon-11 labelled small molecule glucokinase activator, [11C]AZ12504948, 
was synthesised from its aliphatic desmethyl precursor using [11C]methyl iodide, [11C]CH3I. 
Alkylation of the O-position via nucleophilic substitution reaction was successful without 
masking the amide group present in the precursor molecule. Radioligand [11C]AZ12504948 
was evaluated both in vitro and in vivo by autoradiography (ARG) and PET, respectively, to 
visualise intracellular target enzyme glucokinase in the liver and pancreas. These studies 
confirmed the specificity of the radioligand was too low to provide clear signal to noise ratio. 
Thirdly, a small molecule GPR44 specific ligand, AZ compound X, was radiolabelled 
using both carbon-11 and tritium radionuclides, from the sodium sulfinic acid salt precursor, 
using [11C/3H]CH3I for visualising BCM in pancreas. The in vitro binding studies using ARG 
technique demonstrated binding with high specificity to human islets of pancreatic tissues, 
which seems promising for further evaluation in vivo. The presence of islets was confirmed 
by insulin staining, using sequential human pancreatic slices used for ARG.  
Finally, three different fluorine-18 labelled D-peptides were developed and radiolabelled 
using prosthetic group [18F]SFB, for visualising amyloid plaques in the human brain by PET. 
In vitro ARG studies demonstrated higher accumulation of the 18F-peptides in Alzheimer’s 
disease (AD) brain tissue slices compared to that of age-matched control non-AD individual, 
and one of these three 18F-peptides was proven to be the best candidate for further evaluation 
in vivo.  
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6 FUTURE PERSPECTIVE AND CHALLENGES 
 
To find an ideal radioligand for beta cell mass (BCM), imaging has already been proven 
to be a difficult task compared to other research areas. The main challenge in beta cell 
imaging (BCI) is the small volume (1–2%) of endocrine tissue and heterogeneity of islets 
throughout the exocrine pancreas228, in contrast with tumour imaging where the target of 
interest is over expressed. The second challenge is the location of the pancreas, which is 
surrounded by the liver and gastrointestinal system; thereby, excretion route is considered to 
be an obstacle. The hepatobilary excretion of radioligand or radiometabolites results in 
enhanced non-target radioactivity concentrations in the intestinal tract, which makes 
delineation of the pancreatic uptake difficult. The sensitivity of PET imaging is dependent on 
the endogenous expression level of the target protein and the specificity, as well as binding 
affinity of the radioligand with high specific radioactivity. Thus, it is critical to develop 
radionuclide probes with high contrast and beta cell specificity with favourable 
pharmacokinetics. A recent theoretical quantitative analysis of non-invasive BCM imaging 
was published166, where they estimated that the specificity of the radioligand towards β-cells 
should be 100-fold to 1000-fold more than exocrine cells (volume fraction of β-cells and 
exocrine cells; 1:100). With the progression of the disease i.e. decrease of BCM, the 
specificity of the radioligand for β-cells increases exponentially. This is an achievement 
difficult for any radioligand. In any case, in spite of severe methodological challenges, 
progress has been documented for BCM imaging using PET technique. None of the methods 
available so far has proven to predict BCM with a comparable accuracy as the functional PET 
method applied herein162, 165-167. It is important to emphasise that significant efforts have 
recently been underway to identify β-cell specific targets and to design as highly specific 
radioligands to these targets as possible. In the present work, three novel PET radioligands 
were developed for three different molecular targets and explored for BCM imaging in order 
to contribute to the development of so called “ideal” radioligand to gain knowledge about 
diabetes and to assist patients with personalised medical care as well as to advance drug 
discovery, which is finally the ultimate goal.  
Vesicular monoamine transporter type 2 (VMAT2) is a target for imaging BCM, and 
radioligand dihydrotetrabenazine (DTBZ) binds specifically to target VMAT2. Hepatic islet 
transplantation is suffering from poor long-term outcome and graft failure due to inadequate 
graft revascularisation. DTBZ-based radioligands are out of reach to follow hepatic islet 
transplantation, since the liver is responsible for many metabolic pathways i.e. high non-
target signals. Currently, new transplanted sites have been evaluated for increased graft 
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survival, and outcome tissues are bone marrow and brachioradialis (forearm muscle). Our 
developed novel radioligand, [18F]FE-DTBZ-d4, has the characteristics considering the study 
to VMAT2 dense tissue in proximity to cortical bone structure such as intramuscular islet 
transplantation in clinical and preclinical settings. 
The GPR44 receptor, which is highly expressed on the surface of the β-cells in pancreas 
seems a very attractive target for BCI. Based on our experiments, the developed GPR44 
specific radioligand (AZ compound X) demonstrated high specificity towards the islets of 
human pancreas in vitro. The in vivo PET studies in preclinical settings are highly desirable 
to validate this radioligand, in non-diabetic large animals for visualisation and quantification 
of BCM in pancreas. To confirm the specificity of the radioligand, pretreatment or 
displacement studies with cold ligand is required. In order to be able to follow the small 
difference of radioligand uptake in the pancreas of non-diabetic and diabetic subjects i.e. 
BCM, type 1 diabetic model of animal is essential. Unfortunately, GPR44 is not expressed in 
rat pancreas, as several rodent diabetes models are available. Therefore, pig models of T1DM 
or T2DM could be utilised for in vivo evaluation of [11C]AZ Compound X similarly by 
following previously evaluated method229. Radiometabolite analysis of [11C]AZ Compound 
X needs to be performed to follow the stability of the parent radioligand throughout the PET 
scan, especially for the kinetic modelling quantification. 
The main challenge in case of labelled peptide for brain PET imaging is the blood-brain-
barrier (BBB) penetration compared to small molecules. Poor distribution to the brain and 
high nonspecific binding is the main reason for failure of useful CNS radioligands. 
Substances that are able to inhibit Aβ aggregation and reduce its toxic effects are still highly 
desirable for diagnosis and potential therapy. In vitro studies of three 18F-D-peptides using 
ARG technique demonstrated high specificity towards Aβ plaques of AD patient’s brain 
slices compared to non-AD subject, which makes them have a potential for further evaluation 
in vivo by highly sensitive PET imaging techniques. Our preliminary results of dynamic PET 
(in vivo) studies in cynomolgus monkey brain, using these three 18F-D-peptides, 
demonstrated low brain penetration (in the range of 0.1 % of the injected dose corrected for 
blood volume and arterial blood concentration), which makes these 18F-peptides unsuitable as 
PET probe in its current form. The study of metabolism of three 18F-D-peptides during the 
PET experiments showed very high stability and metabolic resistance. In conclusion, desired 
modification of D-enantiomeric peptide (which is fully synthetic) is necessary to improve the 
properties to cross the BBB for future PET studies in order to visualise amyloid plaques in 
AD brain. 
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